Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
An Updated Review of Interleukin-2 Therapy in Cancer and Autoimmune Diseases Publisher Pubmed



Radi H1 ; Ferdosishahandashti E2 ; Kardar GA3 ; Hafezi N4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, Babol University of Medical Sciences, Babol, Iran
  2. 2. Biomedical and Microbial Advanced Technologies (BMAT) Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
  3. 3. National Institute for Genetic Engineering and Biotechnology, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Cellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran

Source: Journal of Interferon and Cytokine Research Published:2024


Abstract

Interleukin-2 (IL-2) is a cytokine that acts in dual and paradoxical ways in the immunotherapy of cancers and autoimmune diseases. Numerous clinical trial studies have shown that the use of different doses of this cytokine in various autoimmune diseases, transplantations, and cancers has resulted in therapeutic success. However, side effects of varying severity have been observed in patients. In recent years, to prevent these side effects, IL-2 has been engineered to bind more specifically to its receptors on the cell surface, decreasing IL-2 toxicities in patients. In this review article, we focus on some recent clinical trial studies and analyze them to determine the appropriate dose of IL-2 drug with the least toxicities. In addition, we discuss the engineering performed on IL-2, which shows that engineered IL-2 increases the specificity function of IL-2 and decreases its adverse effects. Copyright 2024, Mary Ann Liebert, Inc., publishers.
Related Docs
1. Transplantation Immune Responses: Biology, Challenges, and Opportunities Using Biomaterials, Gene Reports (2023)
2. A Novel Nanobody-Based Immunocytokine of a Mutant Interleukin-2 As a Potential Cancer Therapeutic, AMB Express (2024)
3. The Clinical Impact of Mrna Therapeutics in the Treatment of Cancers, Infections, Genetic Disorders, and Autoimmune Diseases, Heliyon (2024)
4. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
5. Human Il-2Rα Subunit Binding Modulation of Il-2 Through a Decline in Electrostatic Interactions: A Computational and Experimental Approach, PLoS ONE (2022)
Experts (# of related papers)
Alireza Biglari (2)
Nima Rezaei (1)